Poliomyelitis and tetanus immunization: antibody responses in patients with cystic fibrosis

Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination

Viral respiratory tract infections exacerbate airway disease and facilitate life-threatening bacterial colonization in cystic fibrosis (CF). Annual influenza vaccination is recommended and vaccines against other common respiratory viruses may further reduce pulmonary morbidity risk. Enteroviruses have been found in nasopharyngeal samples from CF patients experiencing pulmonary exacerbations. Using serology tests, we found that infections by a group of enteroviruses, Coxsackievirus Bs (CVBs), are prevalent in CF. We next showed that a CVB vaccine, currently undergoing clinical development, prevents infection and CVB-instigated lung damage in a murine model of CF. Finally, we demonstrate that individuals with CF have normal vaccine responses to a similar, commonly used enterovirus vaccine (inactivated poliovirus vaccine). Our study demonstrates that CVB infections are common in CF and provides experimental evidence indicating that CVB vaccines could be efficacious in the CF population. The role of CVB infections in contributing to pulmonary exacerbations in CF should be further studied.

•

CVB infections are common in CF

•

A CVB vaccine prevents infection and tissue damage in a model of CF

•

Most people with CF have robust antibody responses to a similar enterovirus vaccine

High-dose hepatitis B vaccine in patients waiting for lung transplantation

STUDY OBJECTIVE

To increase the response rate to hepatitis B vaccine in patients awaiting lung transplantation.

DESIGN

Historically controlled, open-label study.

SETTING

Lung transplant clinic at a university hospital.

SUBJECTS

Twenty-seven consecutive individuals with end-stage pulmonary disease who were enrolled to accrue 15 subjects who would complete the vaccine series before transplantation; and 27 lung transplant recipients who were immunized with the conventional dose before the study and served as historical controls.

INTERVENTION

Intramuscular injection of high-dose hepatitis B vaccine 40 microgram at 0, 1, and 6 months.

MEASUREMENTS AND MAIN RESULTS

Hepatitis B surface antibody (anti-HBs) concentrations were measured 1-2 months after completing the high-dose series. Individuals with undetectable anti-HBs received additional vaccine to a maximum of six doses. The response rate to the series was compared with that in the control group. Seventeen individuals in the high-dose group and 14 controls met the study criterion of complete vaccine series before transplantation. The former had a much higher response rate than the latter (9 [53%] vs 1 [7%], p<0.01). Four of six patients who received additional doses of vaccine seroconverted. Two of them underwent transplantation shortly after completing the three-dose series.

CONCLUSION

The high-dose hepatitis B vaccine series produced a protective immune response in lung transplant recipients; however, the response was suboptimal, and alternative immunization strategies should be studied.